Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
April 12, 2022
Assignees:
Les Laboratories Servier, Institut National de Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifiaue (CNRS)
Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
Type:
Grant
Filed:
October 15, 2019
Date of Patent:
March 9, 2021
Assignees:
GALAPAGOS NV, LES LABORATORIES SERVIER
Inventors:
Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
Type:
Grant
Filed:
January 15, 2019
Date of Patent:
July 14, 2020
Assignees:
LES LABORATORIES SERVIER, VERNALIS (R&d) LTD
Inventors:
Zoltán Szlávik, András Kotschy, Maïa Chanrion, Didier Demarles, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Attila Paczal, Balázs Bálint
Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
Type:
Grant
Filed:
February 8, 2019
Date of Patent:
June 23, 2020
Assignees:
LES LABORATORIES SERVIER, VERNALIS (R&D) LTD
Inventors:
Arnaud Le Tiran, Thierry Le Diguarher, Jérôme-Benoît Starck, Jean-Michel Henlin, Anne-Françoise Guillouzic, Guillaume De Nanteuil, Olivier Geneste, Imre Fejes, János Tatai, Miklós Nyerges, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Didier Durand
Abstract: The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.
Type:
Grant
Filed:
July 22, 2011
Date of Patent:
January 14, 2020
Assignees:
Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Les Laboratories Servier
Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
Type:
Grant
Filed:
February 9, 2017
Date of Patent:
April 16, 2019
Assignees:
LES LABORATORIES SERVIER, VERNALIS (R&D) LTD
Inventors:
Thierry Le Diguarher, Patrick Casara, Jérôme-Benoît Starck, Jean-Michel Henlin, James Edward Paul Davidson, James Brooke Murray, Christopher John Graham, I-Jen Chen, Olivier Geneste, John Hickman, Stéphane Depil, Arnaud Le Tiran, Mikl{dot over (o)}s Nyerges, Guillaume De Nanteuil
Abstract: Process for the enzymatic synthesis of the compound of formula (I): wherein R1 represents a hydrogen atom or an alkyl group. Application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.
Type:
Grant
Filed:
February 5, 2013
Date of Patent:
November 29, 2016
Assignee:
LES LABORATORIES SERVIER
Inventors:
Sandrine Pedragosa-Moreau, François Lefoulon
Abstract: The present disclosure is directed to methods of treating pancreatic cancer in subject using cancer with antibodies that specifically bind to progastrin.
Type:
Grant
Filed:
January 4, 2011
Date of Patent:
November 8, 2016
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS), LES LABORATORIES SERVIER
Abstract: Process for the optical resolution of the compound of formula (I): by chiral chromatography. Application in the synthesis of ivabradine, of its addition salts with a pharmaceutically acceptable acid and of their hydrates.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
January 6, 2015
Assignee:
Les Laboratories Servier
Inventors:
Jean-Michel Lerestif, Jean-Pierre Lecouve, Daniel Dron, Eric Gojon, Maryse Phan
Abstract: The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.
Type:
Grant
Filed:
January 4, 2011
Date of Patent:
December 2, 2014
Assignees:
Les Laboratories Servier, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: Process for the optical resolution of the compound of formula (I): by chiral chromatography. Application in the synthesis of ivabradine, of its addition salts with a pharmaceutically acceptable acid and of their hydrates.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
July 15, 2014
Assignee:
Les Laboratories Servier
Inventors:
Jean-Michel Lerestif, Jean-Pierre Lecouve, Daniel Dron, Eric Gojon, Maryse Phan
Abstract: The present invention provides a mixed crystalline form VIII of agomelatine, its method of preparation, application and pharmaceutical composition. The said mixed crystal consists mainly of crystalline form VI of agomelatine. The said mixed crystalline form is stable and has good reproducibility. Through stability tests, it has been found to be superior to the crystalline form VI in terms of stability. As a result, the crystalline form VIII of the present invention possesses advantages in pharmaceutical preparation.
Abstract: Polymerized micelles comprising polymerized amphiphilic molecules obtained starting from amphiphilic molecules having one or two lipid chains each comprising one or two polymerizable moieties and linked to a polar head.
Type:
Grant
Filed:
April 28, 2009
Date of Patent:
March 4, 2014
Assignees:
Les Laboratories Servier, Commissariat a l'Energie Atomique
Inventors:
Julien Ogier, Eric Doris, François Lefoulon, Thomas Arnauld
Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.
Abstract: The present invention relates to the intermediate compounds for preparation of agomelatine, as well as the preparation methods thereof. The intermediate of the present invention for preparation of agomelatine is compound A as shown in the following formula. Also provided are two novel intermediate compounds. When we use these new intermediate compounds to prepare agomelatine, it is simple to manipulate, well-controlled and with high purity, without complicated operations such as rectification and column chromatography separation, and suitable for industrial production. Meanwhile, the preparation methods of the two new intermediates themselves is simple and high yield, only using the most commonly-used 7-methoxy-tetralone as original starting material and undergoing one step of reaction to obtain the intermediates, followed by one more step of converting the intermediate compounds to desired product agomelatine.